Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor

Article metrics

Abstract

Pre-exposure oral prophylaxis with antiviral drugs is a potential method for preventing transmission of human immunodeficiency virus type 1 (HIV-1). We show that oral delivery of CMPD167, a small molecule that binds to the CCR5 coreceptor, for 10–14 d can protect a substantial proportion of macaques from vaginal infection with a CCR5-using virus (SHIV-162P3). The macaques that became infected despite receiving CMPD167 had reduced plasma viremia levels during the earliest stages of infection.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Plasma viral load in SHIV-162P3-infected animals.

References

  1. 1

    Youle, M. & Wainberg, M.A. AIDS 17, 937–938 (2003).

  2. 2

    Shattock, R.J. & Moore, J.P. Nat. Rev. Microbiol. 1, 25–34 (2003).

  3. 3

    AIDS Vaccine Advocacy Coalition. Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PREP” trials. A special publication of the AIDS Vaccine Advocacy Coalition (AVAC). http://www.avac.org/pdf/tenofovir.pdf. (2005).

  4. 4

    Seibert, C. & Sakmar, T.P. Curr. Pharm. Des. 10, 2041–2062 (2004).

  5. 5

    Barber, C.G. Curr. Opin. Investig. Drugs 5, 851–861 (2004).

  6. 6

    Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T.P. Mol. Pharmacol. 67, 1268–1282 (2005).

  7. 7

    Kuhmann, S.E. et al. J. Virol. 78, 2790–2807 (2004).

  8. 8

    Veazey, R.S. & Lackner, A.A. Nat. Med. 11, 469–470 (2005).

  9. 9

    Veazey, R.S. et al. Nature, published online 30 October 2005 (10.1038/nature04055).

  10. 10

    Veazey, R.S. et al. J. Exp. Med. 198, 1551–1562 (2003).

  11. 11

    Wolinsky, S.M. et al. Virology 328, 19–29 (2004).

  12. 12

    Tsai, C.C. et al. Science 270, 1197–1199 (1995).

  13. 13

    Tsai, C.C. et al. J. Virol. 72, 4265–4273 (1998).

  14. 14

    Marx, P.A. et al. Nat. Med. 2, 1084–1089 (1996).

Download references

Author information

Correspondence to John P Moore.

Ethics declarations

Competing interests

Martin S. Springer is an employee of Merck Inc., but this company did not fund the study.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Veazey, R., Springer, M., Marx, P. et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11, 1293–1294 (2005) doi:10.1038/nm1321

Download citation

Further reading